A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole

Roche, Mirjam de; Daly, Pádraig; Crowley, Vivion; Darby, C; Barnes, Louise

doi:10.1111/j.1365-2230.2006.02332.x

Cited by 6 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical and biochemical remission has been reported in women who terminate the use of estrogens but only when exposure was not prolonged . In one report, suppression of endogenous postmenopausal estrogen levels by the aromatase inhibitor anastrazole, administered for breast cancer prophylaxis, resulted in improvement in PCT symptoms …”

Section: Porphyria Cutanea Tardamentioning

confidence: 99%

“…29 In one report, suppression of endogenous postmenopausal estrogen levels by the aromatase inhibitor anastrazole, administered for breast cancer prophylaxis, resulted in improvement in PCT symptoms. 30 Patients may be advised to limit manual labor as much as possible to minimize mechanical trauma that causes erosions and blistering. Skin lesions can be managed with simple wound care to promote healing, and the judicious treatment of bacterial infections may prevent cutaneous scarring.…”

Section: General Maintenance and Prevention Of Pct Exacerbationsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous porphyrias part II: treatment strategies

et al. 2013

View full text Add to dashboard Cite

The porphyrias are diverse in pathophysiology, clinical presentation, severity, and prognosis, presenting a diagnostic and therapeutic challenge. Although not easily curable, the dermatological manifestations of these diseases, photosensitivity and associated cutaneous pathology, can be effectively prevented and managed. Sun avoidance is essential, and patient education regarding the irreversibility of photocutaneous damage is a necessary corollary. Beyond preventative measures, the care of fragile, vulnerable skin, and pain management, each of the porphyrias has a limited number of unique additional therapeutic options. Many of the treatments have been published only in small case series or anecdotal reports and do not have well-understood nor proven mechanisms of action. This article presents a comprehensive review of available therapeutic options and long-term management recommendations for the cutaneous porphyrias.

show abstract

Section: Porphyria Cutanea Tardamentioning

confidence: 99%

Section: General Maintenance and Prevention Of Pct Exacerbationsmentioning

confidence: 99%